January 12, 2022 5:11pm

As I stated, “after being oversold, when will the overbought syndrome materialize – a kill-joy statement but, soon to be true as it is happening already”

Pre-open Indication results: 5 HITs, 2 MISS

The Biostage Chronicles: Punching the appreciation above its weight - BSTG rose +$0.30, to +$0.40, to +$0.71 to +$0.60 settling at +$0.77 with 44,202 shares traded (3-month average = 2082 shares) to “pimp/pump and promote” the share prices +24.06%. WHY doesn’t BSTG release the number of outstanding shares due to the multiples of over-priced private placements?

If I have learned one thing as a former research analyst, venture and public markets investor then a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

The Dow closed UP +38.30 points (+0.11%); the S&P closed UP +13.28 points (+0.28%) while the Nasdaq closed UP +34.94 points (+0.23%)

 

Henry’omics:

Indexes moved slightly higher Wednesday after a key inflation report showed a historic gain but largely matched expectations.

 

Note: Biogen (BIIB) shares tumbled 6.7% following news that Medicare will only cover the cost for the company’s Alzheimer’s drug Aduhelm for patients with early-stage symptoms who are enrolled in clinical trials. Health care was a weak spot for the market overall, with Merck (MRK) and Amgen (AMGN) both weighing on the Dow.

 

Economic data Docket: December reading for the consumer price index, showed a gain of 7% year over year. That is the biggest jump since 1982, but was in-line with expectations from economists.

  • Also, the average monthly revision to the Labor Department’s jobs report has topped 100,000 in 2021 thus far, the highest level on record.
  • The U.S. economy added 4.9 million jobs in the first 10 months of 2021, according to the initial Labor Department reports. After revisions, that number rose to 6 million.

 

RegMed Investors’ (RMi) pre-open: “cause and effect follow a weak aftermarket. After being oversold, when will the overbought syndrome materialize – a kill-joy statement but, soon to be true as it is happening already.” … https://www.regmedinvestors.com/articles/12254

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Wednesday opened negative at 10 up/24 downs and 1 acquired, stayed negative at the mid-day at 9/25, 1 flat and 1 acquired, ending with a negative close of 6/28 and 1 acquired;

 

Pre-open indication results: 5 Hits < Vericel (VCEL -$2.33), CRISPR Therapeutics (CRSP -$2.85), Intellia Therapeutics (NTLA -$7.28), Mesoblast Limited (MESO; ASX: MSB +$0.06), uniQure NV (QURE +$0.39)> 2 MISS < Biostage (OTCQB: BSTG +$0.77), Editas Medicine (EDIT -$2.27) >

 

Key Metrics:

  • Wednesday - Sector volume was LOW with 1 of the 6-upside having higher than the 3-month average volume with LOW volume of 11 of 25-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday the IBB closed down -1.11% and XBI closed down -3.17%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.79 points or -4.29% at 17.62

 

Jumping with share pricing momentum (6 of 6):

  • Biostage (BSTG +$0.77 after Tuesday’s +$0.87 – the “pump” was in),
  • Ionis Pharmaceuticals (IONS +$0.50 after Tuesday’s +$0.84),
  • uniQure NV (QURE +$0.39 after Tuesday’s -$0.13),
  • BioLife Solutions (BLFS +$0.32 after Tuesday’s -$0.49 and Monday’s +$1.27),
  • Mesoblast (MESO +$0.06),
  • Pluristem (PSTI +$0.04 after Tuesday’s -$0.13 after Monday’s +$0.36),

Hammered in today’s market (10 of 28):

  • Intellia Therapeutics (NTLA -$7.28 after Tuesday’s +$1.01 and Monday’s -$1.51),
  • CRISPR Therapeutics (CRSP -$2.85 after Tuesday’s +$3.62 after Monday’s +$1.43),
  • Fate Therapeutics (FATE -$2.49),
  • Vericel (VCEL -$2.33 after Tuesday’s -$0.36 and Monday’s +$2.46),
  • Editas Medicine (EDIT -$2.27),
  • ReNeuron (RENE.L -$2.20 after Tuesday’s -$2.30 and Monday’s -$2.00),
  • Regenxbio (RGNX -$1.72 after Tuesday’s +$0.43 and Monday’s -$0.93),
  • Ultragenyx (RARE -$1.55 after Tuesday’s -$0.13 and Monday’s -$0.69),
  • Global Blood Therapeutics (GBT -$1.07 after Tuesday’s +$1.06 and Monday’s +$0.54),
  • Sage Therapeutics (SAGE -$1.01 after Tuesday’s +$1.39),

Closing:

  • 1 - Stemline Therapeutics (STML) – acquired

 

January, Q1/2022:

  • Wednesday closed negative with 6 incliners, 28 decliners and 1 acquired

 

JPMorgan Healthcare Conference News Flow:

Precigen (PGEN):

https://finance.yahoo.com/news/precigen-provides-pipeline-corporate-updates-213000252.html         

 

The BOTTOM LINE: Rotation strikes as short-term profit taking messes with the sector.

As I stated this a.m., “After being oversold, when will the overbought syndrome materialize – a kill-joy statement but, soon to be true as it is happening already.”

There are clear losers – Intellia therapeutics (NTLA), Vericel (VCEL) ReNeuron (RENE.L) and CRISPR Therapeutics (CRSP) and winners – Ionis Pharmaceuticals (IONS), BioLife Solutions (BLFS), uniQure NV (QURE) and Chinook Therapeutics (KDNY) as we slide closer to the weekend.

Algorithms, hedge funds and traders continue to punish the cell and gene therapy stocks as valuations “creeped” up.

  • Early January 2022 can deliver some gains but also generate algorithmic based losses.

Reiterating from last year, 2021, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.